HuGE Literature Finder
Records
1
-
30
| ERBB2 exon 20 insertions are rare in Brazilian non-small cell lung cancer. Thoracic cancer 2022 Oct . de Oliveira Cavagna Rodrigo, Zaniolo Beatriz Garbe, de Paula Flávia Escremim, Berardinelli Gustavo Noriz, Santana Iara, da Silva Eduardo Caetano Albino, Dias Josiane Mourão, Jacinto Alexandre Arthur, da Nóbrega Oliveira Rachid Eduardo Noleto, de Marchi Pedro, Leal Letícia Ferro, Reis Rui Manu |
| Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity-matched analysis in a cohort of 147 recurrences. Thoracic cancer 2022 Sep . Xu Fei, Chen Heng-Chi, Xu Haiyan, Li Junling, Hao Xuezhi, Xing Puyuan, Ying Jianming, Wang Y |
| Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non-small cell lung cancer. Thoracic cancer 2022 Sep . Chang Geyun, Li Weihua, Bai Hua, Duan Jianchun, Wang Zhijie, Du Xinyang, Yu Ruofei, Wang Yaxi, Wang Minghao, Zhu Yixiang, Zhang Xue, Li Li, Wan Rui, Wang J |
| Genotyping of cerebrospinal fluid in lung cancer patients with leptomeningeal metastasis. Thoracic cancer 2022 Sep 13 (18): 2574-2583. Nie Naifu, Zhou Haodong, Zhang Kejun, Liu Lan, Luo Nuo, Wang Renyuan, Li Xin, Zhu Mengxiao, Hu Chen, Wang Yubo, Liu Zhulin, Li Li, He Yo |
| Retrospective analysis of independent predictors of progression-free survival in patients with EGFR mutation-positive advanced non-small cell lung cancer receiving first-line osimertinib. Thoracic cancer 2022 Aug . Teranishi Shuhei, Sugimoto Chihiro, Nagaoka Satoshi, Nagayama Hirokazu, Segawa Wataru, Miyasaka Atsushi, Hiro Shuntaro, Kajita Yukihito, Maeda Chihiro, Kobayashi Nobuaki, Yamamoto Masaki, Kudo Makoto, Kaneko Takes |
| A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring EGFR mutations (JMTO LC12-01). Thoracic cancer 2022 Jun 13 (12): 1827-1836. Asami Kazuhiro, Ando Masahiko, Nishimura Takashi, Yokoi Takashi, Tamura Atsuhisa, Minato Koichi, Mori Masahide, Ogushi Fumitaka, Yamamoto Akiyoshi, Yoshioka Hiroshige, Kawahara Masaaki, Atagi Shin |
| Erlotinib with or without bevacizumab as a first-line therapy for patients with advanced nonsquamous epidermal growth factor receptor-positive non-small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study. Thoracic cancer 2022 Jun . Hosomi Yukio, Seto Takashi, Nishio Makoto, Goto Koichi, Yamamoto Noboru, Okamoto Isamu, Tajima Kosei, Kajihara Yusuke, Yamamoto Nobuyu |
| Acute fulminant hepatitis associated with osimertinib administration in a lung cancer patient with chronic hepatitis B: The first mortality case report. Thoracic cancer 2022 2 13 (7): 1091-1094. Kang You-Kuang, Meng Fan-Ch |
| Durable response to durvalumab-based immunochemotherapy in small-cell lung carcinoma transformation from EGFR-mutant non-small cell lung cancer: A case report. Thoracic cancer 2022 1 13 (5): 775-779. Li Yu-Chu |
| First-line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations. Thoracic cancer 2022 1 13 (5): 771-774. Ito Noriaki, Masuda Takeshi, Ooka Ikuko, Hosoya Takatsune, Yamaguchi Kakuhiro, Sakamoto Shinjiro, Horimasu Yasushi, Nakashima Taku, Miyamoto Shintaro, Iwamoto Hiroshi, Fujitaka Kazunori, Hamada Hironobu, Hattori Nobo |
| Clinical impact of rebiopsy among patients with epidermal growth factor receptor-mutant lung adenocarcinoma in a real-world clinical setting. Thoracic cancer 2021 Feb . Nam Yunha, Kim Ho Cheol, Kim Young-Chul, Jang Seung Hun, Lee Kye Young, Lee Shin Yup, Lee Sang Hoon, Lee Sung Yong, Yoon Seong Hoon, Ryu Jeong-Seon, Jang Tae Won, Chang Yoon Soo, Kim Seung Joon, Park Chan Kwon, Lee Jeong Eun, Jung Chi Young, Choi Chang-M |
| Clinical influence of switching companion diagnostic tests for EGFR-TKs from Therascreen to Cobas v2. Thoracic cancer 2021 Feb . Uchibori Ken, Takano Natsuki, Manabe Ryo, Tsugitomi Ryosuke, Ogusu Shinsuke, Tozuka Takehiro, Sakamoto Hiroaki, Yoshida Hiroshi, Amino Yoshiaki, Ariyasu Ryo, Kitazono Satoru, Yanagitani Noriko, Nishio Mako |
| Clinical outcomes and radiation pneumonitis after concurrent EGFR-tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer. Thoracic cancer 2021 Jan . Xu Kunpeng, Liang Jun, Zhang Tao, Zhou Zongmei, Chen Dongfu, Feng Qinfu, Xiao Zefen, Hui Zhouguang, Lu Jima, Wang Xin, Deng Lei, Liu Wenyang, Wang Jianyang, Zhai Yirui, Wang Jie, Bi Nan, Wang Luh |
| Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib. Thoracic cancer 2021 12 13 (3): 394-403. Long Yaping, Xiong Qi, Song Qi, Li Yao, Li Xiaoyan, Qin Boyu, Huang Ziwei, Hu Yi, Yang |
| The role of EGFR-TKIs as adjuvant therapy in EGFR mutation-positive early-stage NSCLC: A meta-analysis. Thoracic cancer 2021 04 12 (7): 1084-1095. Lin Chutong, Hu Fengling, Chu Hongling, Ren Peng, Ma Shanwu, Wang Jingdi, Bai Jie, Han Xuan, Ma Shaoh |
| Association of hOGG1-Cys variants with occurrence of p53 and EGFR deletion mutations in non-small cell lung cancer. Thoracic cancer 2020 Dec . Chen Ming-Jenn, Shen Ching-Ju, Wang Lee, Chen Po-Ming, Chen Chih-Yi, Lee Hu |
| Comparison of the analytical performance between the Oncomine Dx Target Test and a conventional single gene test for epidermal growth factor receptor mutation in non-small cell lung cancer. Thoracic cancer 2020 Dec . Sakaguchi Tadashi, Iketani Akemi, Furuhashi Kazuki, Nakamura Yuki, Suzuki Yuta, Ito Kentaro, Fujiwara Kentaro, Nishii Yoichi, Katsuta Koji, Taguchi Osamu, Hataji Osa |
| Comprehensive genomic profiling of Brazilian non-small cell lung cancer patients (GBOT 0118/LACOG0418). Thoracic cancer 2020 Dec . Mascarenhas Eldsamira, Gelatti Ana Caroline, Araújo Luiz Henrique, Baldotto Clarissa, Mathias Clarissa, Zukin Mauro, Werutsky Gustavo, Pacheco Patricia, Gomes Rafaela, de Castro Gilberto, de Lima Vladmir Cordei |
| First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer. Thoracic cancer 2020 Dec . Su Po-Lan, Chen Chian-Wei, Wu Yi-Lin, Lin Chien-Chung, Su Wu-Ch |
| Phase II open-label multicenter study to assess the antitumor activity of afatinib in lung cancer patients with activating epidermal growth factor receptor mutation from circulating tumor DNA: Liquid-Lung-A. Thoracic cancer 2020 Dec . Park Cheol-Kyu, Lee Sung-Yong, Lee Jae Cheol, Choi Chang-Min, Lee Shin Yup, Jang Tae-Won, Oh In-Jae, Kim Young-Ch |
| Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: A phase II single-arm prospective clinical trial. Thoracic cancer 2020 Nov . Lu Zhi-Qin, Cai Jing, Wang Xia, Wei Jian-Ping, Zeng Zhi-Min, Huang Long, Liu An-W |
| Superior efficacy of immunotherapy-based combinations over monotherapy for EGFR-mutant non-small cell lung cancer acquired resistance to EGFR-TKIs. Thoracic cancer 2020 Oct . Yang Lu, Hao Xuezhi, Hu Xingsheng, Wang Zhijie, Yang Ke, Mi Yuling, Yang Yaning, Xu Haiyan, Yang Guangjian, Wang Y |
| EGF+61 A>G polymorphism does not predict response to first-generation EGFR tyrosine kinase inhibitors in lung cancer patients. Thoracic cancer 2020 Sep . Leal Leticia F, Laus Ana C, Cavagna Rodrigo, de Paula Flavia E, de Oliveira Marco A, Ribeiro Dayana M, Hassan Fernanda M, Miziara José E, da Silva Eduardo C Albino, da Silva Vinicius D, De Marchi Pedro, Reis Rui |
| Status of 10 targeted genes of non-small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution. Thoracic cancer 2020 Jul . Li Dan, Ding Li, Ran Wenwen, Huang Yan, Li Guangqi, Wang Chengqin, Xiao Yujing, Wang Xiaonan, Lin Dongliang, Xing Xiaomi |
| High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes. Thoracic cancer 2020 Apr . Li Yan, Zhang Fanshuang, Yuan Pei, Guo Lei, Jianming Ying, He J |
| Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer. Thoracic cancer 2020 Apr . Wei Xue-Wu, Gao Xin, Zhang Xu-Chao, Yang Jin-Ji, Chen Zhi-Hong, Wu Yi-Long, Zhou Qi |
| Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. Thoracic cancer 2020 Mar . Kishikawa Takayuki, Kasai Takashi, Okada Masahiko, Nakachi Ichiro, Soda Sayo, Arai Ryo, Takigami Ayako, Sata Masafu |
| Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failure. Thoracic cancer 2020 Feb . Mizuno Takaaki, Horinouchi Hidehito, Watanabe Sho, Sato Jun, Morita Ryo, Murakami Shuji, Goto Yasushi, Kanda Shintaro, Fujiwara Yutaka, Yamamoto Noboru, Ohe Yuichi |
| Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status. Thoracic cancer 2020 Feb . Arrieta Oscar, Ramírez-Tirado Laura-Alejandra, Caballé-Perez Enrique, Mejia-Perez Alberto, Zatarain-Barrón Zyanya Lucia, Cardona Andrés F, Lozano-Ruíz Francisco, Segura-González Manuel, Cruz-Rico Graciela, Maldonado Federico, Rosell Rafa |
| Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor. Thoracic cancer 2020 Jan . Kwon Byoung Soo, Cho Young Hyun, Yoon Shin-Kyo, Lee Dae Ho, Kim Sang-We, Kwon Do Hoon, Lee Jae Cheol, Choi Chang-M |
- Page last reviewed:Feb 1, 2023
- Page last updated:Feb 07, 2023
- Content source: